Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Atria is a Dividend King with an impressive track record for dividend growth. Eli Lilly has been raising its dividend at a more impressive pace than Altria in recent years. Altria has an ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug. Hours after Hims & Hers posted a blog ...

Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer.

Showcasing a limited-edition, hand-painted print, the new collection features coordinating styles for kids and adults. By Erin Lassner E-Commerce Writer If you purchase an independently reviewed ...

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is ...

MNC pharma major Eli Lilly has launched Mounjaro (tirzepatide), a weekly injection for obesity and type 2 diabetes, after obtaining approval from India’s Central Drugs Standard Control ...

Weight loss drugs such as Mounjaro help the body manage blood sugar more effectively, make one feel less hungry, and slow digestion, so the person feels full longer. Mounjaro, chemically known as ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Lilly beats Novo Nordisk to launch weight-loss drug in India Mounjaro's 5 mg vial priced at around $50, 2.5 mg at about $40 Drug's pricing may limit accessibility in India, analyst says Novo's ...